Evidence map›Paper›PMID 18823687›Full record

Trial reportAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2009

Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.

Femke Waanders, Vishal S Vaidya, Harry van Goor, Henri Leuvenink, Kevin Damman, Inge Hamming, Joseph V Bonventre, Liffert Vogt, Gerjan Navis

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.

  1. Pooled it
  2. Altered dietary salt intake for people with chronic kidney disease.The Cochrane database of systematic reviews · 2021
    Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Kidney international reports · 2021
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Renal Impairment in Chronic Hepatitis B: A Review.Diseases (Basel, Switzerland) · 2018
    Review
  16. Review
  17. Relationship of proximal tubular injury to chronic kidney disease as assessed by urinary kidney injury molecule-1 in five cohort studies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2016
    Observational
  18. Article
  19. Follow-Up Renal Assessment of Injury Long-Term After Acute Kidney Injury (FRAIL-AKI).Clinical journal of the American Society of Nephrology : CJASN · 2016
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Femke WaandersDepartment of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Vishal S Vaidya
Harry van Goor
Henri Leuvenink
Kevin Damman
Inge Hamming
Joseph V Bonventre
Liffert Vogt
Gerjan Navis
University Medical Center Groningen · NLUniversity of Groningen · NLBrigham and Women's Hospital · USHarvard University · US

Funding

KIDNEY INJURY MOLECULE-1 IN EPITHELIAL REPAIRR01DK072381 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2005 to 2025
$8.6M
Mechanisms of Ischemic Kidney Injury and RepairR01DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI JOSEPH VINCENT BONVENTRE · 1987 to 2026
$6.2M
Mechanisms of Ischemic Kidney Injury and RepairR37DK039773 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1993 to 2021
$5.2M
Biomarkers in Acute Kidney InjuryR33DK074099 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2007 to 2009
$1.9M
Biomarkers in Acute Kidney InjuryR21DK074099 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 2005 to 2006
$516k
Technology and Endothelial Biology of Kidney Injury Molecule-1K99ES016723 · NIEHS · BRIGHAM AND WOMEN'S HOSPITAL · PI VAIDYA, VISHAL S. · 2007 to 2007
$90k
NIDDK NIH HHS R01 DK039773NIDDK NIH HHS R01 DK072381NIDDK NIH HHS R21 DK074099NIDDK NIH HHS R33 DK074099NIDDK NIH HHS R37 DK039773NIEHS NIH HHS K99 ES016723
6 · The paper itself

Abstract

backgroundTubulointerstitial damage plays an important role in chronic kidney disease (CKD) with proteinuria. Urinary kidney injury molecule 1 (KIM-1) reflects tubular KIM-1 and is considered a sensitive biomarker for early tubular damage. We hypothesized that a decrease in proteinuria by using therapeutic interventions is associated with decreased urinary KIM-1 levels. STUDY

designPost hoc analysis of a randomized, double-blind, placebo-controlled, crossover trial. SETTING &

participants34 proteinuric patients without diabetes from our outpatient renal clinic.

interventionStepwise 6-week interventions of losartan, sodium restriction (low-sodium [LS] diet), their combination, losartan plus hydrochlorothiazide (HCT), and the latter plus an LS diet. OUTCOMES & MEASUREMENTS: Urinary excretion of KIM-1, total protein, and N-acetyl-beta-d-glucosaminidase (NAG) as a positive control for tubular injury.

resultsMean baseline urine protein level was 3.8 +/- 0.4 (SE) g/d, and KIM-1 level was 1,706 +/- 498 ng/d (increased compared with healthy controls; 74 ng/d). KIM-1 level was decreased by using placebo/LS (1,201 +/- 388 ng/d; P = 0.04), losartan/high sodium (1,184 +/- 296 ng/d; P = 0.09), losartan/LS (921 +/- 176 ng/d; P = 0.008), losartan/high sodium plus HCT (862 +/- 151 ng/d; P = 0.008) and losartan/LS plus HCT (743 +/- 170 ng/d; P = 0.001). The decrease in urinary KIM-1 levels paralleled the decrease in proteinuria (R = 0.523; P < 0.001), but not blood pressure or creatinine clearance. 16 patients reached target proteinuria with protein less than 1 g/d, whereas KIM-1 levels normalized in only 2 patients. Urinary NAG level was increased at baseline and significantly decreased during the treatment periods of combined losartan plus HCT only. The decrease in urinary NAG levels was not closely related to proteinuria. LIMITATIONS: Post hoc analysis.

conclusionsUrinary KIM-1 level was increased in patients with nondiabetic CKD with proteinuria and decreased in parallel with proteinuria by using losartan, sodium restriction, their combination, losartan plus HCT, and the latter plus sodium restriction. These results are consistent with the hypothesis of amelioration of proteinuria-induced tubular damage. Long-term studies are warranted to evaluate whether targeting treatment on KIM-1 can improve outcomes in patients with CKD with proteinuria.

Indexed as

AcetylglucosaminidaseAdultAgedAntihypertensive AgentsBiomarkersChronic DiseaseCombined Modality TherapyCross-Over StudiesDiureticsDouble-Blind MethodDrug Therapy, CombinationFemaleHepatitis A Virus Cellular Receptor 1HumansHydrochlorothiazideKidney DiseasesAcetylglucosaminidaseAntihypertensive AgentsBiomarkersDiureticsHAVCR1 protein, humanHepatitis A Virus Cellular Receptor 1HydrochlorothiazideLosartanMembrane GlycoproteinsReceptors, VirusSodium, Dietary

Identifiers

PMID18823687
PMCPMC3298772
OpenAlexW1997832120

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.